癌症2001，Vol.20Issue(4)：403-405,3.
CVDLP与CHOP方案治疗Ⅲ/Ⅳ期淋巴母细胞性淋巴瘤诱导缓解期疗效比较
Comparing CVDLP with CHOP in Induction Treatment for Patients with Advanced Lymphoblastic Lymphoma
孙晓非 1管忠震 1周中梅 1张力 1李宇红 1夏忠军 1黄河 1黄慧强 1何友兼 1陈丽昆 1陈茹琴 1田维华1
作者信息
摘要
Abstract
Objective: This study was designed to improve complete remission(CR) rate in the patients with advanced lymphoblastic lymphoma by using early extensive induction chemotherapy. Method:A total of 11 cases of untreated lymphoblastic lymphoma in Stage Ⅲ /Ⅳ were received CVDLP regimen, including cytoxan(CTX) 1000 mg/m2 d1， vincristine(VCR) 1.5 mg/m2 d1,d8,d15,d21， Adriamycin(ADR) 40 mg/m2 d1， d2， d21， L-asparaginase(L-ASP) 10000 U/m2 d15～24， Prednison 60 mg/m2 d1～28， gradually decreased dosage at d15. methotrexate＋ Ara-C IT qw× 4. Efficacy were evaluated at d28～35. Simultaneously,retrospective analysis for 9 cases of untreated lymphoblastic lymphoma in Stage Ⅲ /Ⅳ treated with 2 cycles of CHOP were made. Efficacy were evaluated at d35. Results: CVDLP group: 10/11 cases of patients achieved CR, and 1/11 case had PR, rate of complete remission was 90.9％ ;10/11 cases had Grade Ⅳ hematological toxicity,1/11 cases had Grade Ⅲ hematological toxicity(WHO). CHOP group:3/9 got CR;5/9 got PR;1/9 had MR,rate of complete remission was 33％ . 3/9 had Grade Ⅲ hematology toxicity;6/9 had GradeⅡ hematological toxicity. Conclusion:CVDLP regimen can induce higher CR rate than CHOP regimen in untreated lymphoblastic lymphoma with Stage Ⅲ /Ⅳ , but hematology toxicity was also higher than CHOP regimen. However this induction regimen is safe and viable with strengthening supportive care.关键词
晚期淋巴母细胞性淋巴瘤/剂量强度分类
医药卫生引用本文复制引用
孙晓非,管忠震,周中梅,张力,李宇红,夏忠军,黄河,黄慧强,何友兼,陈丽昆,陈茹琴,田维华..CVDLP与CHOP方案治疗Ⅲ/Ⅳ期淋巴母细胞性淋巴瘤诱导缓解期疗效比较[J].癌症,2001,20(4):403-405,3.
